Stock screenerAll disclosures →
EDGAR →
VRCA
Conviction 73HealthcareScan · Thu, Jun 25, 2026VRCA$6.28+7.35%
ResistanceSupportVol 14Vol MA14 50.58K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price6.28
Change+7.35%
Gap+5.13%
Rel volume4.12×
Avg volume45.49K
Avg $ vol270.02K
SMA 205.89
SMA 506.33
SMA 2005.92
Price vs 50-0.75%
Price vs 200+6.06%
MA stackmixed
50/200 cross—
Supertrenddown · 7.12
RSI (14)55
MACD hist0.04
MACD crossbull · 0d
Stoch %K / %D65 / 42
ADX (14)9
+DI / −DI21 / 17
RSI divergence—
MACD divergence—
ATR %+8.33%
ADR %8.06%
52w high9.10
52w low0.5226
From 52w high-30.99%
Above 52w low+1101.68%
New 52w highNo
SqueezeOn · 10d
Bollinger width12.03%
%B1.05
Donchian pos65.34%
Donchian high6.80
Donchian low5.30
AVWAP (52w high)7.18
vs AVWAP high-12.51%
AVWAP (52w low)4.42
vs AVWAP low+42.03%
OBV trendUp
Chaikin MF (20)-0.48
Today vs 20d4.12×
Avg vol (14d)50.58K
Avg vol (20d)45.49K
Avg $ vol (20d)270.02K
Market cap107.88M
RS 3m (vs SPY)+18.32%
RS 6m (vs SPY)-32.93%
RS line new highNo
Trend template4/8
Technical rank49.4
1 week+7.72%
1 month+4.32%
3 months+35.93%
6 months-20.61%
1 year+950.17%
YTD-24.34%
P/E-6.03
P/B6.72
P/S14.26
P/FCF-6.12
EPS-1.68
Div yield—
ROE-111.40%
ROA-46.11%
Debt/Eq0.00
Current2.10
EV/EBITDA—
Gross margin—
Net margin-236.40%
Rev growth47.66%
EPS growth76.64%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value87.28M
Revenue12.7M
Net income-9.68M
Gross profit—
Free cash flow-17.63M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out17.18M
Employees76
ListedFri, Jun 15, 2018
Free float5.63M
Float %35.2%
Short interest379.28K
Days to cover9.3d
Short volume43.8%
Squeeze score56 / 100
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeB
Conviction73 / 100
Pattern quality—
Tech rank49.4 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance8.35
Support5.39
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in VRCA
No recent disclosed trades by Congress in VRCA. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in VRCA · 7 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Eichenfield Lawrence Director · Stock Option (right to buy) · 2026-06-05 | Grant | 16K | $0 | 2026-06-05 | 2026-06-09 |
PRYGOCKI MARK A SR Director · Stock Option (right to buy) · 2026-06-05 | Grant | 16K | $0 | 2026-06-05 | 2026-06-09 |
Corcoran Gavin Director · Stock Option (right to buy) · 2026-06-05 | Grant | 16K | $0 | 2026-06-05 | 2026-06-09 |
Rosenberg Noah L. CMO · Employee Stock Option (right to buy) · 2026-06-05 | Grant | 233.84K | $0 | 2026-06-05 | 2026-06-09 |
Rieger Jayson CEO and President · Employee Stock Option (right to buy) · 2026-06-05 | Grant | 512.27K | $0 | 2026-06-05 | 2026-06-09 |
Nguyen Diem Director · Stock Option (right to buy) · 2026-06-05 | Grant | 16K | $0 | 2026-06-05 | 2026-06-09 |
Zawitz David Chief Operating Officer · Employee Stock Option (right to buy) · 2026-06-05 | Grant | 171.34K | $0 | 2026-06-05 | 2026-06-09 |
SEC filings
EDGAR filings in VRCA · 1 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.